ArticleCurrent microbiology2026
Preparation and Serological Evaluation of an Inactivated Trivalent Oil Emulsion Vaccine for Avian Fowl Adenovirus (FAdV) Containing - 8a, 8b, and 11 Serotypes.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trivalent fowl adenovirus vaccine (serotype-4/8b/11) provides efficient protection with long duration of immunity.Journal of veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inclusion body hepatitis (IBH), caused by fowl adenovirus (FAdV) species D and E, results in significant economic losses for the poultry industry. This study aimed to evaluate the immunogenicity of an inactivated trivalent FAdV vaccine in SPF chickens, specifically assessing the effects of antigen payload, thimerosal addition, and booster immunization on antibody titers. Results demonstrated a clear dose-response, with higher antigen payloads eliciting a more prolonged immune response compared to the lowest dose. Thimerosal was confirmed to be a safe preservative, showing no negative impact on antibody development. Furthermore, a booster immunization significantly increased antibody levels, but this effect was observed only in the group receiving the high-payload vaccine, with peak titers at weeks 2 and 3 post-vaccination. These findings indicate that a high-dose trivalent inactivated FAdV vaccine, administered with a booster, is highly immunogenic and represents a promising strategy for the effective prevention and control of IBH.
Indexed as
Identifiers
41593398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.